A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder

Journal of Clinical Psychiatry

Volumn 68, Issue 11, 2007, Pages 1663-1672

  Liebowitz, Michael R ^a,c   Yeung, Paul P ^b   Entsuah, Richard ^b  

^a Columbia University ^*  (United States)

^b PFIZER INC   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HOSTILITY; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NERVOUSNESS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; XEROSTOMIA; YAWNING;

EID: 37049001204     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1105     Document Type: Article

References (44)

1. Kessler RC, Berglund P, Demier O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
2. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-1475
3. Agency for Health Care Policy and Research. Depression in primary care: detection, diagnosis, and treatment. Clin Pract Guidel Quick Ref Guide Clin 1993:1-20
4. Frasure-Smith N, Lesperance F, Juneau M, et al. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999;61:26-37
5. Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005;28:2668-2672
6. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216-226
7. Clement EM, Odontiadis J, Franklin M. Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. J Chromatogr B Biomed Sci Appl 1998;705:303-308
8. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-199
9. Andree TH, Rosenzweig-Lipson S, Lin Q, et al. Preclinical evidence for antidepressant and anxiolytic efficacy of the new dual serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate (DVS). Presented at the 27th annual meeting of the Collegium Internationale Neuro- Psychopharmacologicum; July 9-13, 2006; Chicago, Ill
10. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-665
11. Parks V, Patat A, Behrle J, et al. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single oral doses of sustained-release desvenlafaxine succinate (DVS-SR) in healthy subjects. Presented at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics; Mar 2-5, 2005; Orlando, Fla
12. Shilling A, Young-Sciame R, Leung L. Comparison of inhibitory effects of desvenlafaxine succinate, venlafaxine, S,S duloxetine, paroxetine, sertraline and bupropion on human cytochrome P450 activities. Presented at the 13th annual North American meeting of the International Society for the Study of Xenobiotics; Oct 25-27, 2005; Maui, Hawaii
13. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-688
14. Septien-Velez L, Pitrosky B. Randomized, double-blind, placebo-controlled, study of desvenlafaxine succinate in major depressive disorder. Presented at the 159th annual meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada
15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatrie Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
16. Hamilton M. Hamilton Rating Scale for Depression (HAM-D). In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000: 526-529
17. Guy W. 028 CGI Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Bethesda, Md: US Department of Health, Education and Welfare, National Institute of Mental Health; 1976:217-222
18. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 1982;18:69-77
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
20. Sheehan DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:113-115
21. Heun R, Burkart M, Maier W, et al. Internal and external validity of the WHO Well-Being Scale in the elderly general population. Acta Psychiatr Scand 1999;99:171-178
22. Huskisson EC. Measurement of pain. Lancet 1974;2:1127-1131
23. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44(2):77-87
24. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand 1975;51:161-170
25. Entsuah R. ETRANK: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. J Biopharm Stat 1996;6:457-475
26. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-181
27. Khan A, Khan SR, Shankles EB, et al. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol 2002;17:281-285
28. Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration Summary Basis of Approval reports. Neuropsychopharmacology 2003;28:552-557
29. Khan A, Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol 2005;6:221-226
30. Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002;22:40-45
31. Khan A, Brodhead AE, Kolts RL, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005;39:145-150
32. Khan A, Brodhead AE, Kolts RL. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol 2004;19:157-160
33. Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774-779
34. Kirmayer LJ, Robbins JM, Dworkind M, et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-741
35. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335
36. Delgado PL. Common pathways of depression and pain. J Clin Psychiatry 2004;65(suppl 12):16-19
37. Stahl SM. Does depression hurt? J Clin Psychiatry 2002;63:273-274
38. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000;55:915-920
39. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400
40. Bradley RH, Barkin RL, Jerome J, et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003;10:318-323
41. Entsuah R, Li Y. Venlafaxine vs SSRIs: comparison of complete somatic symptom resolution [poster]. Presented at the 156th annual meeting of the American Psychiatry Association; May 17-22, 2003; San Francisco, Calif
42. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697-706
43. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53
44. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multi-center trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-356